Mizuho lowers Ideaya Biosciences stock price target to $43 on pipeline review

Mizuho has lowered its price target on Ideaya Biosciences (IDYA) to $43.00 from $55.00, while reiterating its Outperform rating, following a comprehensive pipeline review that adjusted timelines for key assets like darovasertib and IDE397. Despite the price target reduction, Mizuho cited "significant pipeline optionality" with six unmodeled assets and the company's strong liquidity. This adjustment comes amidst varied analyst sentiment, including a new Buy rating from TD Cowen and a Neutral from Goldman Sachs, reflecting continued market interest in Ideaya's oncology pipeline and upcoming clinical data readouts for darovasertib and IDE849.

Analysis

Ideaya Biosciences (IDYA) is navigating a period of recalibrated expectations, as evidenced by Mizuho's 22% price target reduction to $43.00, despite maintaining an Outperform rating. The adjustment stems from revised timelines for key pipeline assets: the pivotal efficacy readout for the lead drug, darovasertib, has been tightened to year-end 2025, while launch assumptions for IDE397 have been delayed following a partnership dissolution. Despite these setbacks, the company's financial health remains a significant strength, with a market capitalization of $2.26 billion, a balance sheet holding more cash than debt, and a robust current ratio of 13.92x. This strong liquidity supports its ambitious pipeline of nine assets. Analyst sentiment is mixed but engaged; while Mizuho and RBC Capital ($30 PT) reiterate Outperform ratings, citing "significant pipeline optionality" with six assets not yet in financial models, TD Cowen initiated with a Buy, and Goldman Sachs resumed coverage with a Neutral rating. Upcoming clinical data, including a Phase 2 darovasertib presentation in October 2025 and Phase 1 data for IDE849, represent critical catalysts that will likely influence future analyst ratings and valuations.

Key Decisions for Investors

• Investors should weigh the long-term valuation upside from the deep, nine-asset pipeline against near-term execution risks highlighted by the revised clinical and launch timelines for its two lead assets.
• Closely monitor upcoming clinical catalysts, particularly the Phase 2 darovasertib data in October 2025 and the pivotal study readout by year-end 2025, as these are the most significant events that could de-risk the lead program and re-rate the stock.
• Consider the company's strong balance sheet, with more cash than debt and a 13.92x current ratio, as a key mitigating factor that provides a substantial funding runway for development without immediate dilution risk.
• Acknowledge the divergent analyst sentiment, with price targets from $30 to $43 and ratings from Neutral to Buy, which underscores the current uncertainty and high-risk, high-reward profile pending further clinical validation.